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Dezsi / Cardiovascular Research 47 (2000) 642 -644 643 reduce long-term mortality in severe congestive heart coupled constitutive B receptor. Bradykinin is a potent 2 failure (for reviews see [5, 6] ). Similar beneficial effects vasodilator. Its effect is mediated by multiple mechanisms: were found in the Assessment of Treatment with Lisinopril endothelium-derived nitric oxide, release of prostacyclin, and Survival Study (ATLAS) [7] . In addition, prolonged and the so-called endothelium-derived hyperpolarizing ACE inhibitor therapy reversed left ventricular hyperfactor (EDHF) [11] . Bradykinin plays no significant role in trophy. ACE inhibitors had also beneficial effects on the the blood pressure regulation in normotension, but in vessels, improving endothelial function [6] . Long-term hypertension increased bradykinin levels seem to mediate perindopril treatment increased arterial diameter and comcompensatory vasodilation. Kinins also increase the perpliance [8] .
meability of post-capillary venules, which results in an Whether ACE inhibitors can favorably alter the course elevated plasma filtration to tissues. On the other hand, of diseases, such as atherosclerotic vascular disease, kallikrein may also elevate blood pressure by directly diabetic microalbuminuria and nephropathy, is a matter of converting prorenin to renin [12] . debate. Will cardiovascular benefit be greater than that
The hemostatic and the kallikrein-kinin systems are attributable to the decrease in blood pressure? Could ACE interconnected at least via two important mechanisms. One inhibitors be used for primary and secondary prevention in of them relates to the formation of endothelial mediators of such diseases? This is currently one of the hottest issues in the fibrinolysis. Vasoactive agents, of which bradykinin is typescripts, as well as in electronic publications, of the 1000-fold more potent than the others, induce the release research field [5,6,9]. Before we attempt to answer these of tissue plasminogen activator (t-PA) into the circulation questions, let us take a closer look at the action of ACE [13] . Endothelial cells are major sites of t-PA synthesis, inhibitors on the renin-angiotensin and the kallikreinwhich is substantially enhanced by blood flow-induced kinin systems.
sheer stress. In plasma most of the t-PA forms complex Functioning of the renin-angiotensin system, and the with its physiological inhibitor PAI-1, which is also an participation of angiotensin converting enzyme in that endothelial cell product. Endothelial cell surface has a t-PA process is well known. Briefly, renin forms angiotensin I binding site, bound t-PA functions as one of the plasacting on angiotensinogen, a globulin of liver origin.
minogen activators, and plasmin serves as the effector of Angiotensin I is converted to the octapeptide angiotensin II fibrinolysis. Note, that kallikrein stimulates the formation by ACE. ACE is a carboxypeptidase localized on the of another plasminogen activator, urokinase [12] . endothelial cell surface in the lung and other vascular beds.
The other mechanism involves the contact activation of Renin is released into the circulation from juxtaglomerular Factor XII (Hageman) during which this factor gets into cells in the wall of afferent arterioles to kidney glomeruli.
contact with a negatively charged surface (e.g. collagen), Various factors including reduced renal perfusion pressure, and in turn XIIa further activates the intrinsic pathway of salt depletion, and beta-receptor activation stimulate renin blood coagulation. In addition to the initiation of thrombus release, which in turn promotes the formation of angiotenformation, XIIa cleaves plasma prekallikrein, resulting in sin I and angiotensin II at the endothelium. Physiological plasma kallikrein, and then the latter will produce bradyeffects of angiotensin II are mediated via the G-protein kinin [12] . The consequent t-PA release inhibits microcoupled AT receptors. The renin-angiotensin system thrombus formation, whose dissolution is also much more 1 participates in both short-term and long-term blood preseffective if t-PA is incorporated during its formation [14] . sure regulations. Immediate hypertensive effect of anFrom the above mechanisms it arises that the angiotengiotensin II is due to an increase in peripheral vascular sin-converting enzyme elevates blood pressure producing resistance subsequent to direct vasoconstriction and angiotensin II, as well as inactivating bradykinin, while peripheral sympatho-adrenal stimulation. Long-term pres-ACE inhibitors can effectively reduce blood pressure. In sure elevation is the consequence of sodium retention, addition, there is a possibility for ACE inhibitors to aldosterone secretion, and direct effects on kidney hemoenhance fibrinolysis by preserving bradykinin from its dynamics. Finally, increased angiotensin II concentration breakdown. However, the exact relationship of the reninpromotes cardiac hypertrophy and vascular remodelling angiotensin and the kinin systems with the fibrinolytic [10] .
mediators in man has not been established yet. In this issue The significance of the kallikrein-kinin system in of Cardiovascular Research Labinjoh et al. [14] addressed cardiovascular regulation is not always recognized. Kinins this question. They determined the local effect of intraare produced both within the vascular system and in arterial angiotensin II and bradykinin on the local forearm different tissues. In the plasma, high molecular weight release of t-PA and PAI-1. They have shown, that angiotenkininogens are cleaved by plasma kallikrein yielding the sin II, contrary to earlier results, does not directly affect nonapeptide bradykinin, while in tissues kallidin (lysillocal release of t-PA or PAI-1 from endothelial cells. bradykinin) is formed from low molecular weight However, systemic effects of angiotensin II may explain kininogens [10] . Plasma kinins are quickly metabolized by PAI-1 reducing effect of ACE inhibitor therapy, a previous kininase II (same as ACE) and kininase I enzymes. The finding. On the other hand, they found that intra-arterial effects of bradykinin are mediated via the G-protein bradykinin infusion substantially, and dose-dependently rinolysis in man.
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